Astrazeneca Plc ADR (AZN) Stock Price, Quote & News

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modi...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 44 20 3749 5000

Fax: 44 1223 352 858

Website: www.astrazeneca.com

Address:

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom

mikesterz7 Dec. 4 at 8:15 PM

$PFE $AZN $NVO $LLY AstraZeneca, Pfizer, Novo Nordisk, and Eli Lilly are among the major pharmaceutical companies that have made commitments to invest in the U.S.

0 · Reply

HedgeAlerts Dec. 4 at 7:37 AM

Hedge Alert Live - Protect Your Portfolio Contract: $AZN $90.00 Put · DEC 19, 2025 Exp Entry Price: $1.23 - $1.31 Exit Price Target: $2.79 Profit Margin: +127% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

finansbull88 Dec. 4 at 7:21 AM

$AZN

0 · Reply

GJ_Rockabilt Dec. 4 at 7:11 AM

$AZN Okay, tell your Company to get off of Factor Biosciences Dr. Angel's Patents, now, please. Patent Infringement is unethical. Doubt I will Buy ANYTHING here, until he is PAID.

0 · Reply

RunnerSignals Dec. 3 at 8:33 PM

$AMGN $AZN $CRVO $NCLH $PHR more stock upgrades today highlight top picks https://stocksrunner.com/news/2025-12-03-stock-upgrades-today-highlight-top-picks

0 · Reply

RunnerSignals Dec. 3 at 8:31 PM

$AMGN $AZN $CRVO $NCLH $PHR Stock Upgrades Today Highlight Top Picks https://stocksrunner.com/news/2025-12-03-stock-upgrades-today-highlight-top-picks

0 · Reply

Chipwars Dec. 3 at 7:57 PM

$AZN AstraZeneca price target raised to 15,500 GBp from 14,200 GBp at Guggenheim

0 · Reply

Chipwars Dec. 3 at 7:55 PM

$AZN AZ has previously said that, given the massive unmet need among patients with high blood pressure that does not respond to current antihypertensive medicines, baxdrostat could become a $5 billion-a-year product. There are around 1.4 billion people worldwide living with hypertension, and in the US approximately half of patients on multiple drugs to control their blood pressure do not meet their treatment targets.

0 · Reply

Chipwars Dec. 3 at 7:51 PM

$AZN https://www.investing.com/news/analyst-ratings/astrazeneca-stock-price-target-raised-to-gbp155-by-morgan-stanley-93CH-4387549

0 · Reply

Chipwars Dec. 3 at 7:26 PM

$AZN "Today marks an important milestone for Pangaea Data as we begin a new multi-year collaboration with AstraZeneca, supported by Microsoft and NVIDIA, to bring multimodal, clinical-grade AI into everyday care at scale," Vibhor Gupta, founder and CEO of Pangaea Data, told MobiHealthNews.

0 · Reply

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

CRM

Dec 4, 2025, 7:00 AM EST - 21 hours ago

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Dec 2, 2025, 9:18 AM EST - 2 days ago

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

Dec 1, 2025, 10:15 AM EST - 3 days ago

BREAKING: Trump strikes major deal with UK on drug pricing

EWU EWUS FKU FLGB FXB GSK

Nov 26, 2025, 12:18 PM EST - 8 days ago

Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies

NVO

Nov 24, 2025, 12:58 PM EST - 10 days ago

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Nov 23, 2025, 7:01 PM EST - 11 days ago

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

Nov 21, 2025, 8:22 PM EST - 13 days ago

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

Nov 21, 2025, 6:23 PM EST - 13 days ago

Why AstraZeneca Stock Bumped Higher Today

Nov 21, 2025, 2:05 PM EST - 13 days ago

AstraZeneca to invest $2 billion as part of US manufacturing push

Nov 21, 2025, 2:05 PM EST - 13 days ago

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

Nov 18, 2025, 4:21 PM EST - 16 days ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

JNJ LLY MDT MRK NVO OLMA PFE

Nov 18, 2025, 8:25 AM EST - 16 days ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN BIIB GILD GSK JNJ LLY

Nov 14, 2025, 3:19 PM EST - 20 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV JNJ LLY MRK NVO PFE XLV

Nov 14, 2025, 7:06 AM EST - 20 days ago

Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

LLY

Nov 11, 2025, 7:45 AM EST - 23 days ago

FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines

Nov 11, 2025, 3:42 AM EST - 24 days ago

AstraZeneca hits record high, cements lead as UK's biggest stock

Nov 10, 2025, 5:20 PM EST - 24 days ago

Why AstraZeneca Stock Was a Winner Today

Nov 10, 2025, 1:39 PM EST - 24 days ago

AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

Nov 9, 2025, 4:33 PM EST - 25 days ago

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Nov 7, 2025, 9:00 AM EST - 27 days ago

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

Nov 6, 2025, 4:42 PM EST - 4 weeks ago

Why AstraZeneca Stock Topped the Market on Thursday

Nov 6, 2025, 4:26 PM EST - 4 weeks ago

AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 3:28 PM EST - 4 weeks ago

AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)

Nov 6, 2025, 7:00 AM EST - 4 weeks ago

AstraZeneca's 9M and Q3 2025 Financial Results

Nov 6, 2025, 4:12 AM EST - 4 weeks ago

AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO

Nov 6, 2025, 2:39 AM EST - 4 weeks ago

AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal

Nov 6, 2025, 2:04 AM EST - 4 weeks ago

AstraZeneca beats third-quarter revenue and profit expectations

Nov 3, 2025, 11:11 AM EST - 4 weeks ago

AstraZeneca wins shareholder backing for NYSE listing in US pivot

Nov 3, 2025, 11:06 AM EST - 4 weeks ago

AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US

Nov 3, 2025, 9:17 AM EST - 4 weeks ago

BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025

Oct 31, 2025, 1:19 AM EDT - 5 weeks ago

FTSE Index shares to watch next week: BT, BP, IAG, AstraZeneca, Marks & Spencer

Oct 24, 2025, 4:51 AM EDT - 6 weeks ago

AstraZeneca found in breach of industry code over Symbicort marketing, industry body says

Oct 20, 2025, 6:53 AM EDT - 6 weeks ago

AstraZeneca hails major breakthroughs with breast-cancer drugs

Oct 19, 2025, 2:32 AM EDT - 6 weeks ago

AstraZeneca's Datroway extends survival in aggressive breast cancer

Oct 18, 2025, 10:33 AM EDT - 6 weeks ago

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

Oct 17, 2025, 4:17 PM EDT - 6 weeks ago

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

Oct 17, 2025, 4:08 PM EDT - 6 weeks ago

US FDA expands use of Amgen, AstraZeneca's drug for sinus infection

AMGN

Oct 16, 2025, 9:48 AM EDT - 7 weeks ago

2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades

LLY

Oct 15, 2025, 10:00 AM EDT - 7 weeks ago

AstraZeneca unveils expanded manufacturing facility in Texas

Oct 13, 2025, 7:00 AM EDT - 7 weeks ago

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

Oct 12, 2025, 9:25 AM EDT - 7 weeks ago

Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump

Oct 10, 2025, 7:30 PM EDT - 7 weeks ago

Trump announces drug-pricing deal with pharma giant

Oct 10, 2025, 6:30 PM EDT - 7 weeks ago

Trump reaches deal with AstraZeneca to lower U.S. drug prices

Oct 10, 2025, 6:23 PM EDT - 7 weeks ago

AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising.

Oct 10, 2025, 6:17 PM EDT - 7 weeks ago

Pres. Trump announces deal with AstraZeneca to lower U.S. drug prices

Oct 10, 2025, 6:05 PM EDT - 7 weeks ago

TrumpRx makes more drug pricing moves and strikes a deal with AstraZeneca

Oct 10, 2025, 5:54 PM EDT - 7 weeks ago

Trump says AstraZeneca to offer drugs to US at discounted prices

Oct 10, 2025, 3:45 PM EDT - 7 weeks ago

AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.

Oct 10, 2025, 3:45 PM EDT - 7 weeks ago

AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices, according to a person familiar with the matter

mikesterz7 Dec. 4 at 8:15 PM

$PFE $AZN $NVO $LLY AstraZeneca, Pfizer, Novo Nordisk, and Eli Lilly are among the major pharmaceutical companies that have made commitments to invest in the U.S.

0 · Reply

HedgeAlerts Dec. 4 at 7:37 AM

0 · Reply

finansbull88 Dec. 4 at 7:21 AM

$AZN

0 · Reply

GJ_Rockabilt Dec. 4 at 7:11 AM

$AZN Okay, tell your Company to get off of Factor Biosciences Dr. Angel's Patents, now, please. Patent Infringement is unethical. Doubt I will Buy ANYTHING here, until he is PAID.

0 · Reply

RunnerSignals Dec. 3 at 8:33 PM

$AMGN $AZN $CRVO $NCLH $PHR more stock upgrades today highlight top picks https://stocksrunner.com/news/2025-12-03-stock-upgrades-today-highlight-top-picks

0 · Reply

RunnerSignals Dec. 3 at 8:31 PM

$AMGN $AZN $CRVO $NCLH $PHR Stock Upgrades Today Highlight Top Picks https://stocksrunner.com/news/2025-12-03-stock-upgrades-today-highlight-top-picks

0 · Reply

Chipwars Dec. 3 at 7:57 PM

$AZN AstraZeneca price target raised to 15,500 GBp from 14,200 GBp at Guggenheim

0 · Reply

Chipwars Dec. 3 at 7:55 PM

0 · Reply

Chipwars Dec. 3 at 7:51 PM

$AZN https://www.investing.com/news/analyst-ratings/astrazeneca-stock-price-target-raised-to-gbp155-by-morgan-stanley-93CH-4387549

0 · Reply

Chipwars Dec. 3 at 7:26 PM

0 · Reply

Chipwars Dec. 3 at 7:24 PM

$AZN Astrazeneca will benefit hugely by it's use of AI. https://www.mobihealthnews.com/news/exclusive-pangaea-data-astrazeneca-leverage-ai-detect-rare-and-hard-diagnose-diseases

0 · Reply

Chipwars Dec. 3 at 7:21 PM

$AZN https://finance.yahoo.com/news/astrazeneca-azn-named-one-bofa-065750704.html

0 · Reply

Chipwars Dec. 3 at 7:11 PM

$AZN https://www.zacks.com/stock/news/2798941/why-astrazeneca-azn-is-a-top-momentum-stock-for-the-long-term?cid=CS-STOCKTWITS-HL-tale_of_the_tape|zacks_education_momentum_score-2798941&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_548_2798941

0 · Reply

LDT123 Dec. 3 at 5:34 PM

$ALT Dear Santa, My list is simple: This. Is. It. P.S. Since I was a good boy this year—and because $NVO could really use a celebratory bump—feel free to let them bring a higher counter-offer. And congrats to $AZN on getting a 'zero tariff' gift from their Christmas list early.

1 · Reply

JulietAlfaTango Dec. 3 at 5:21 PM

$AZN https://www.investing.com/news/analyst-ratings/astrazeneca-stock-price-target-raised-to-gbp155-by-morgan-stanley-93CH-4387549

0 · Reply

JulietAlfaTango Dec. 3 at 5:18 PM

$AZN https://investing.com/news/analyst-ratings/astrazeneca-stock-price-target-raised-to-gbp155-by-morgan-stanley-93CH-5134821

0 · Reply

ZacksResearch Dec. 3 at 3:09 PM

Big catalyst move for $AZN? The FDA just granted a Priority Review to baxdrostat — that’s no small signal. AstraZeneca’s NDA for baxdrostat is now on the fast track for hard-to-control hypertension, with an FDA decision expected in the second quarter of 2026. Full breakdown here 👉 https://www.zacks.com/stock/news/2798965/azns-baxdrostat-gets-fda-priority-tag-for-uncontrolled-hypertension?cid=sm-stocktwits-2-2798965-teaser-23245&ADID=SYND_STOCKTWITS_TWEET_2_2798965_TEASER_23245

0 · Reply

ZacksResearch Dec. 3 at 2:09 PM

$AZN's bold move with baxdrostat could redefine hypertension treatment! 🚀 The FDA's priority review of AstraZeneca's NDA for baxdrostat could lead to it being the first aldosterone synthase inhibitor approved in the U.S. by Q2 2026, aiming to tackle hard-to-control hypertension based on data from the BaxHTN study. Discover if this breakthrough could fuel AZN's stock further 👉 https://www.zacks.com/stock/news/2798965/azns-baxdrostat-gets-fda-priority-tag-for-uncontrolled-hypertension?cid=sm-stocktwits-2-2798965-body-23237&ADID=SYND_STOCKTWITS_TWEET_2_2798965_BODY_23237

0 · Reply

Power2k Dec. 3 at 1:36 PM

$ALT why I think Pemvi is superior to FGF21s and THRb agonists? The latter don’t offer weight-loss benefits at all, plus they still pose significant side-effects, and if you would try to pair FGF21s or THRb agonists with GLP-1s or Amylin in some sort of combo approach, the tolerability issues will be enormous. On top of MASH resolution, Pemvi offers weight-loss effects with best lean muscle-retaining benefit which is second-to-none. It’s like having one drug working as a combo by itself, largely reducing side effects commonly seen in traditional combo therapies. Pemvi also beats Survodutide (another GLP-1/GCGR class of drug), as Pemvi shows much better tolerability and much earlier onset of MASH resolving effects. Pemvi is BIC, period. $SNY $AZN

0 · Reply

LiquidThetaOptions Dec. 3 at 1:32 AM

💎 LiquidTheta® Live Actionable Trade Asset: $AZN Contracts: $AZN January 15, 2027 $92 Calls Scale in: $7.04- $8.60 Scale out: $27.38-$46.94 Profit Potential : 189% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

prismmarketview Dec. 2 at 6:17 PM

(NASDAQ: $AZN) #AstraZeneca's Baxdrostat was accepted for FDA Priority Review for resistant hypertension. The NDA is supported by Phase 3 data showing significant blood pressure reduction. A decision is expected by Q2 2026. https://prismmarketview.com/fda-accepts-astrazenecas-baxdrostat-for-priority-review-in-resistant-hypertension#

0 · Reply

Power2k Dec. 2 at 4:25 PM

$ALT Why I think Pemvidutide totally beats Zealand/BI's Survodutide? #1 Pemvi’s 24-week topline MASH resolution rate (≈52–59%) is similar to Survodutide’s highest reported dose (62% at 4.8 mg) — but Survo’s results are at 48 weeks while Pemvi’s topline biopsy readout is at 24 weeks, which demonstrates an much earlier onset of efficacy of Pemvi as compared to Survo. #2 Survodutide (48 weeks): ≥1-stage fibrosis improvement occurred in 34% (2.4 mg), 36% (4.8 mg), 34% (6.0 mg) vs 22% with placebo which is stat significant. Pemvi (IMPACT 24-wk topline): Fibrosis improvement without worsening of MASH reported in 31.8% (1.2 mg) and 34.5% (1.8 mg) vs 25.9% for placebo which is not stat sig, however, this is a 24-week readout, and (imo) will achieve stat sig in the upcoming 48-wk readout. #3 Pemvi's safety profiles beat Survodutide's by a lot: Survo has a way higher rate of discontinuation due to AE (around 16-25%) while Pemvi shows only 0 to 1.2% of AE-related discontinuation. $SNY $AZN

4 · Reply

Market Cap	279.66B
Revenue (ttm)	54.07B
Net Income (ttm)	7.04B
EPS (ttm)	N/A
PE Ratio	19.73
Forward PE	19.55
Profit Margin	13.01%
Debt to Equity Ratio	0.67

Volume	5,250,800
Avg Vol	5,467,490
Day's Range	N/A - N/A
Shares Out	3.10B
Stochastic %K	44%
Beta	0.32
Analysts	Strong Sell
Price Target	$92.06